Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax Inc. (NASDAQ: NVAX) shares are trading higher Monday after the company completed its rolling submission to Health Canada for the authorization of its protein-based COVID-19 vaccine candidate. Novavax was up 12.79% at $167.86 Monday afternoon.

Technical Levels To Watch In Novavax Stock As It Looks To Bounce Back

A whale with a lot of money to spend (and possibly insider knowledge) has taken a noticeably bearish stance on Novavax. Looking at options history for Novavax (NASDAQ:NVAX) we detected 80 strange trades.

Check Out What Whales Are Doing With NVAX

On Novavax's (NVAX) upcoming third-quarter earnings call, investor focus is likely to be on the company's progress with its COVID-19 vaccine candidate NVX-CoV2373.

Novavax (NVAX) to Report Q3 Earnings: What's in the Cards?

Novavax just got a thumbs up from Indonesia. Patient investors are hoping this means NVAX stock will be a winner in the coming year.

NVAX Stock Shoots Higher Thanks to Global Progress on Its Covid-19 Vaccine

The biotech announced three major regulatory updates for its COVID-19 vaccine this morning.

Why Novavax Stock Is on Fire Today

The biotech company's vaccine has been authorized for emergency use in Indonesia and has been submitted for authorization in Canada and the EU.

Novavax's Covid-19 Vaccine Gets Its First Authorization—and More Could Come Soon

The shot marks the first time an older, protein-based shot has been approved to fight Covid-19 and the first vaccine Novavax has been able to bring to market in its 34-year history.

Novavax Covid-19 Vaccine Gets First Emergency Authorization In Indonesia—Here's What You Need To Know

Novavax Inc (NASDAQ: NVAX) has completed its rolling submission to Health Canada for the authorization of its protein-based COVID-19 vaccine candidate.  In addition, the Company has completed the submission of all data and modules to the European Medicines Agency (EMA) to support the final regulatory review of its dossier.

Why Are Novavax Shares Trading Higher Today?

GAITHERSBURG, Md. and PUNE, India, Nov. 1, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt.

Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia

Health Canada filing marks first protein-based COVID-19 vaccine submitted for authorization to regulatory authorities in Canada Submission of all modules required for regulatory review, including CMC and clinical data, are now complete for European Medicines Agency GAITHERSBURG, Md., Nov. 1, 2021 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion of its rolling submission to Health Canada for authorization of its COVID-19 vaccine candidate, the first filing of a protein-based COVID-19 vaccine in Canada.

Novavax Files for COVID-19 Vaccine Authorization with Health Canada and Completes Submission for Rolling Review to European Medicines Agency

NVAX benefits from several near-term catalysts that will push the stock higher, making it a better buy than more mature enterprises. The post Novavax Is a Much Better Growth Buy Than Moderna Here appeared first on InvestorPlace.

Novavax Is a Much Better Growth Buy Than Moderna Here

NVAX stock's prospects in November depend upon regulatory developments regarding its Covid-19 vaccine candidate The post Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Analyst Who Found Microsoft at $0.38 Names #1 Pick for the AI Boom America's #1 EV Stock Still Flying Under the Radar

Novavax Stock Is a Buy for Long-Term Investors on Its Pipeline Alone

Novavax stock offers a unique opportunity to invest in a late stage biotech built on cutting-edge vaccine technology, NVAX stock has surged on its Covid-19 vaccine potential, but don't forget its work on a universal vaccine for seasonal influenza. The post Novavax Stock Rises as UK Covid Vax Okay Sought, Other Growth Anticipated appeared first on InvestorPlace.

Novavax Stock Rises as UK Covid Vax Okay Sought, Other Growth Anticipated

Shares of Novavax Inc. NVAX, -1.19% shot up 6.8% in premarket trading Monday, after the biotechnology company said it has completed its rolling submission to Canada's health authorities, Health Canada, for the authorization of its COVID-19 vaccine candidate.

Novavax stock jumps after submission of data on COVID-19 vaccine candidate to Health Canada, EMA completed

Atea Pharmaceuticals

Omeros

Each for reasons of their own, Atea Pharmaceuticals, Omeros, and Novavax have had a very tough time this year.

3 Beaten-Down Biotech Stocks -- Can They Recover?

Did Novavax Just Pass Its Biggest Hurdle?

Novavax's manufacturing targets are on track and just increased dramatically to 2.4 billion doses per year. EUAs have been filed in multiple countries and more are coming soon. Novavax already has orders for about 2 billion doses, far more than most people realize. I expect it will sell about 2.7 billion doses between 2021 and 2022.

Novavax: A Great Buy On Quickly Growing Production, Super Low Valuation And Many EUA Filings

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $200,000 In Novavax To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Corp. - October 29, 2021) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Novavax ("Novavax, Inc." or the "Company") (NASDAQ: NVAX).If you suffered losses exceeding $200,000 investing in Novavax stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information:...

Novavax Shareholder Alert

Politico's article about Novavax's inability to manufacture its Covid-19 vaccine wasn't good for NVAX stock. Down 16% since, should you buy?

Novavax Just Caught a Big Break

American Well Corporation

Novocure

You might want to avoid stuffing your portfolio with them.

3 Healthcare Stocks That Could Be Turkeys in November

Novavax Inc. NVAX, +6.41% said Friday it has filed for provisional approval of its COVID-19 vaccine in Australia. "The company's application to the TGA marks the first complete application for provisional approval of a protein-based COVID-19 vaccine in Australia," the company said in a statement.

Novavax files for provisional approval of COVID-19 vaccine in Australia

GAITHERSBURG, Md., Oct. 29, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, today announced the completion of its rolling submission to the Therapeutic Goods Administration (TGA) for provisional approval of its COVID-19 vaccine candidate.

Novavax Files for Provisional Approval of its COVID-19 Vaccine in Australia

Can Novavax Make a Comeback?

BioNTech SE

Comirnaty, the COVID-19 vaccine produced by Pfizer-BioNTech, has been recommended for children between 5 and 11 years old. The White House has acquired sufficient vaccines from Pfizer-BioNTech. It is targeted for distribution to more than 25,000 pediatricians' offices, hospitals, and pharmacies.

Novavax Is Finally Coming For BioNTech's Dominance

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

News for Novavax Stock (NVAX)